Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children.

[1]  Shabir A Madhi,et al.  A role for Streptococcus pneumoniae in virus-associated pneumonia , 2004, Nature Medicine.

[2]  S. Romero-Steiner,et al.  Measurement of Serum Bactericidal Activity Specific for Haemophilus influenzae Type b by Using a Chromogenic and Fluorescent Metabolic Indicator , 2004, Clinical Diagnostic Laboratory Immunology.

[3]  K. Auranen,et al.  Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. , 2003, Vaccine.

[4]  S. Madhi,et al.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. , 2003, The New England journal of medicine.

[5]  L. Bodin,et al.  Why the rise in Haemophilus influenzae type b infections? , 2003, The Lancet.

[6]  C. Muirhead,et al.  UK nuclear-test veterans , 2003, The Lancet.

[7]  M. Theodoridou,et al.  Haemophilus influenzae type b conjugate vaccine‐induced immunological memory in symptomatic HIV‐1‐infected children , 2003, AIDS.

[8]  J. McVernon,et al.  Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis , 2003, The Lancet.

[9]  M. Steinhoff,et al.  Conjugate Hib vaccines , 2003, The Lancet.

[10]  S. Madhi,et al.  Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection , 2002, The Pediatric infectious disease journal.

[11]  J. Deeks,et al.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. , 2000, JAMA.

[12]  P. Wollan,et al.  Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. , 1999, Vaccine.

[13]  M. Fowler,et al.  The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group. , 1998, The Pediatric infectious disease journal.

[14]  D. Goldblatt,et al.  Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. , 1998, The Journal of infectious diseases.

[15]  R. van Furth,et al.  Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Sood,et al.  Immunity to Haemophilus influenzae type b after reimmunization with oligosaccharide CRM197 conjugate vaccine in children with human immunodeficiency virus infection. , 1997, The Pediatric infectious disease journal.

[17]  C. Giaquinto,et al.  Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. , 1996, The Pediatric infectious disease journal.

[18]  A. Cnaan,et al.  Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. , 1996, Archives of pediatrics & adolescent medicine.

[19]  S. Sood,et al.  Immunity to Haemophilus influenzae type b polysaccharide capsule after vaccination with the complete series of oligosaccharide CRM197 conjugate vaccine in infants with human immunodeficiency virus infection. , 1996, The Journal of pediatrics.

[20]  P. Paradiso,et al.  The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus‐infected and uninfected infants , 1995, The Pediatric infectious disease journal.

[21]  C. Giaquinto,et al.  Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. , 1995, The Pediatric infectious disease journal.

[22]  P. Mäkelä,et al.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. , 1983, The Journal of infectious diseases.

[23]  G. Hussey,et al.  Epidemiology of invasive Haemophilus influenzae infections in Cape Town, South Africa. , 1994, Annals of tropical paediatrics.

[24]  P. Anderson,et al.  Human serum activities against Hemophilus influenzae, type b. , 1972, The Journal of clinical investigation.